US7172241090 - Common Stock
PHASEBIO PHARMACEUTICALS INC
NASDAQ:PHAS (11/2/2022, 8:00:01 PM)
After market: 0.0533 -0.02 (-23.97%)0.0701
-0.02 (-26.21%)
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
PHASEBIO PHARMACEUTICALS INC
1 Great Valley Pkwy Ste 30
Malvern PENNSYLVANIA 19355
P: 16109816500.0
CEO: Jonathan P. Mow
Employees: 60
Website: https://phasebio.com/
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday!
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
We're starting off the day with an overview of the biggest pre-market stock movers on Tuesday and the latest news this morning!
Here you can normally see the latest stock twits on PHAS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: